Impact of Atogepant on the Improvement in the Severity of Overall Migraine Symptoms Using PGI-S: Post hoc Analyses from ADVANCE, ELEVATE, and PROGRESS (P9-12.006)
To evaluate the proportion of participants treated with atogepant (Ato) versus placebo (Pbo) who had at least moderate symptoms at baseline and had an improvement in severity of overall migraine symptoms at Weeks 4, 8, and 12 in three phase 3 Ato trials.
Authors
- Teshamae Monteith (ORCID: https://orcid.org/0000-0001-8912-252X)
- Belinda Savage‐Edwards
- Hsiangkuo Yuan (ORCID: https://orcid.org/0000-0002-4536-9974)
- Pranav Gandhi (ORCID: https://orcid.org/0009-0008-8317-7712)
- Jessica Ailani (ORCID: https://orcid.org/0000-0001-8106-4927)
- Kandavadivu Umashankar (ORCID: https://orcid.org/0000-0003-1138-8533)
- Umer Najib (ORCID: https://orcid.org/0000-0002-1116-9229)
- Jonathan Stokes
- Molly Duan
Institutions
- University of Miami (US)
- Thomas Jefferson University (US)
- Georgetown University (US)
- MedStar Georgetown University Hospital (US)
- West Virginia University Hospitals (US)
- AbbVie (United States) (US)
- AbbVie (Japan)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000208522
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00